Boehringer Ingelheim expands cancer research at its Vienna site
Vienna oncology research centre Research & development Vienna oncology centre opening Group photo Inauguration of Angelika ...
Boehringer Ingelheim faces second hung jury in Chicago Zantac trial
The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, ...
Cancer-focused biotech Notable Labs lays off 65% of workforce
This Peninsula biotech company started as a way to find a cancer drug for a co-founder's father. It now layoffs show it’s ...
Medscape1d
'Call to Action': Greater CVD Focus Urged for Type 1 Diabetes
Several studies revealed high cardiovascular risk in people with type 1 diabetes, including in those who are asymptomatic and ...
BioSpace1d
Boehringer, Insilico Appear to Break Through Against IPF
Clinical trial results shared by Boehringer Ingelheim and Insilico Medicine showed improvement in idiopathic pulmonary ...
healthcare-in-europe.com1d
KRAS “degrader” could lead to treatment for millions of cancer patients
New research from the University of Dundee shows potential breakthrough for hard to treat cancers. Experts from the ...
Critical Mass With Law.com’s Amanda Bronstad: Johnson & Johnson Files Third Talc Bankruptcy, Zantac Mistrial Gives Plaintiffs Their Fourth Loss
In this month’s trial, which began on Aug. 28, Eric Olson ( Olson Grimsley) and Ashley Keller ( Keller Postman) represented ...
Small-molecule drug shows potential for hard to treat cancers
Experts from the University of of Dundee's Centre for Targeted Protein Degradation (CeTPD), working with Boehringer Ingelheim scientists, have developed a breakthrough small-molecule drug, a "protein ...
Boehringer's Nerandomilast Meets Primary Endpoint In Pivotal Phase-III FIBRONEERTM-IPF Study
Boehringer Ingelheim announced today that the FIBRONEERTM-IPF trial met its primary endpoint, which was the absolute change ...
Another Mistrial in Zantac: Fourth Illinois Jury Fails to Award Damages
On Wednesday, a jury in Cook County Circuit Court in Illinois ended in a mistrial in a case against Zantac manufacturer ...
Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration
Boehringer is advancing the development of SZN-413 to prepare it for potential future clinical testingSZN-413 is a bi-specific antibody targeting ...
Science Daily1d
Potential breakthrough for hard to treat cancers
Experts have developed a breakthrough small-molecule drug, a 'protein degrader'. This molecule, called ACBI3, could potentially lead to new therapies independent of KRAS mutation type, improving ...